GHTM

Global Health and Tropical Medicine

  • GHTM
    • About GHTM
    • Governance
    • Impact
    • Members
      • Population health, policies and services
        • PPS PhD members
        • PPS non PhD members
      • TB, HIV and opportunistic diseases and pathogens
        • THOP PhD members
        • THOP non PhD members
      • Vector-borne diseases
        • VBD PhD members
        • VBD non PhD members
      • Individual Health Care
        • IHC PhD members
        • IHC non PhD members
      • Tech & Admin support
    • Scientific Advisory Board
  • Research
    • Cross-cutting issues
      • Global Pathogen Dispersion and Population Mobility
      • Drug Discovery and Drug Resistance
      • Diagnostics
      • Public Health Information
      • Fair Research Partnerships
    • Research Groups
      • PPS – Population health, policies and services
      • THOP – TB, HIV and opportunistic diseases and pathogens
      • VBD – Vector borne diseases
      • IHC – Individual health care
    • Research in numbers
      • 2023
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
    • Projects
      • Ongoing Projects
      • Completed Projects
  • Outreach
    • Events
    • News
    • Policy Support & Community Outreach
  • Publications
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
    • 2019
    • 2018
    • 2017
    • 2016
    • 2015
  • Capacity Building
    • Education
      • Master Theses
      • PhD Theses
    • International
  • Infrastructures
  • Networks & Partnerships
  • Reports
    • GHTM
    • Scientific Advisory Board
    • FCT
Home / Archives for Vercauteren J

Expected HIV-1 etravirine resistance after treatment failure with efavirenz and/or nevirapine

  • Authors: Camacho R, Carvalho AP, Grossman Z, Levy I, Ram D, Rudich H, Vercauteren J, Beheydt G, Vandamme AM, Van Laethem K
  • Journal: Antiviral Therapy
  • Link: https://apps.webofknowledge.com/full_record.do?product=UA&search_mode=GeneralSearch&qid=2&SID=Z1yZbyGlNxI3xGo9eDj&page=1&doc=1

Read More

Cellular HIV-1 DNA levels in drug sensitive strains are equivalent to those in drug resistant strains in newly-diagnosed patients in Europe

  • Authors: Balotta C, Clotet B, Demetriou VL, Grossman Z, Jørgensen LB, Kostrikis LG, Kousiappa I, Lepej SZ, Levy I, Nielsen C, Paraskevis D, Poljak M, Roman F, Ruiz L, Schmidt JC, Van de Vijver DA, Vercauteren J, Vandamme AM, Van Laethem K
  • Journal: PLoS One
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/20544014

BACKGROUND:
HIV-1 genotypic drug resistance is an important threat to the success of antiretroviral therapy and transmitted resistance has reached 9% prevalence in Europe. Studies have demonstrated that HIV-1 DNA load in peripheral blood mononuclear cells (PBMC) have a predictive value for disease progression, independently of CD4 counts and plasma viral load.
Read More

Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients.

  • Authors: Albert J, Åsjö B, Balotta C, Boucher CA, Bruckova M, Camacho RJ, Clotet B, Coughlan S, Deforche K, Grossman Z, Hamouda O, Horban A, Korn K, Kostrikis LG, Kücherer C, Libin P, Liitsola K, Nielsen C, Paraskevis D, Poljak M, Puchhammer-Stöckl E, Riva C, Ruiz L, Schmit JC, Schuurman R, Sönnerborg A, SPREAD-programme, Staneková D, Stanojevic M, Struck D, Theys K, Van de Vijver DA, Van Laethem K, Vandamme AM, Vercauteren J, Wensing AMJ
  • Journal: Retrovirology
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=Treatment-associated+polymorphisms+in+protease+are+significantly+associated+with+higher+viral+load+and+lower+CD4+count+in+newly+diagnosed+drug-naive+HIV-1+infected+patients

BACKGROUND:
The effect of drug resistance transmission on disease progression in the newly infected patient is not well understood. Major drug resistance mutations severely impair viral fitness in a drug free environment, and therefore are expected to revert quickly. Compensatory mutations, often already polymorphic in wild-type viruses, do not tend to revert after transmission.
Read More

HIV-1 transmitted drug resistance in Latin America and the Caribbean: what do we know?

  • Authors: Bello DC, Gomez-Lopez A, Pineda-Peña AC, Sussmann O, Van Laethem K, Vandamme AM, Vercauteren J
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/?term=HIV-1+Transmitted+Drug+Resistance+in+Latin+America+and+the+Caribbean%3A+What+Do+We+Know%3F

Latin America and the Caribbean countries have increased the scaling-up of antiretroviral treatment in the last years. The increase of transmitted drug resistance has been feared due to the worrisome indicators associated with the emergence of drug resistance and monitored by the World Health Organization (WHO). Consequently, our aim was to review all relevant studies […]
Read More

The demise of multidrug- resistant HIV-1: The national time trend in Portugal

  • Authors: Aguas MJ, Camacho RJ, Carvalho AP, Duque LM, Faria D, Faria T, Mansinho K, Peres S, Teófilo E, Theys K, Valadas E, Vandamme AM, Vera J, Vercauteren J
  • Journal: Journal of Antimicrobial Chemotherapy
  • Link: http://www.ncbi.nlm.nih.gov/pubmed/23228933

Despite a decreasing mortality and morbidity in treated HIV-1 patients, highly active antiretroviral treatment (HAART) can still fail due to the development of drug resistance. Especially, multidrug-resistant viruses pose a threat to efficient therapy. We studied the changing prevalence of multidrug resistance (MDR) over time in a cohort of HIV-1-infected patients in Portugal.
Read More

  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • Next Page »

About GHTM

GHTM is a R&D Unit that brings together researchers with a track record in Tropical Medicine and International & Global Health. It aims at strengthening Portugal's role as a leading partner in the development and implementation of a global health research agenda. Our evidence-based interventions contribute to the promotion of equity in health and to improve the health of populations.

Contacts

Rua da Junqueira, 100
1349-008 Lisboa
Portugal

+351 213 652 600

  • E-mail
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

Map

  • Events
  • Research Groups
  • Cross-cutting issues
© Copyright 2025 IHMT-UNL All Rights Reserved.
  • Universidade Nova de Lisboa
  • Fundação para a Ciência e a Tecnologia

    UIDB/04413/2020
    UIDP/04413/2020

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok